Navigation Links
Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire/ -- A presentation at the 14th International Conference on Prenatal Diagnosis and Therapy (ISPD) in Vancouver, BC, will highlight Biocept's I.D.Rh(D) Prenatal Diagnostic. I.D.Rh(D) is the first in a series of noninvasive prenatal diagnostic tests that can be performed with a simple maternal blood sample.

The I.D.Rh(D) test diagnoses the Rh(D) status of a fetus in an Rh(D) negative pregnancy, and can be performed as early as ten weeks of gestation. The test isolates fetal DNA circulating in the mother's whole blood, using Biocept's proprietary I.D.(TM) (Isolating Fetal DNA) platform technology (U.S. patents pending). The fetal DNA is analyzed in Biocept's CLIA-accredited clinical laboratory to determine Rh(D) genotype. Similar noninvasive tests have been available routinely in some countries outside the US.

The presentation, to be given by Andrew Brooks, Ph.D., University of Medicine and Dentistry of New Jersey, concludes that isolation of fetal DNA from maternal whole blood for quantitative real-time PCR and Rh(D) genotyping is suitable for routine testing. Testing of multiple markers and controls, which I.D.Rh(D) offers, allows for a high degree of accuracy.

"We are very pleased to see our excellent clinical results validated in an independently reviewed scientific forum such as ISPD," said Gordon F. Janko, president and CEO of Biocept. "The I.D.Rh(D) test, which is now being used commercially, is an important step forward in noninvasive prenatal testing, and provides a higher level of personalized medicine for patients. It is the first of several noninvasive prenatal diagnostics developed in Biocept's laboratories, based on our novel and proprietary technology."

I.D.Rh(D) is the only fetal Rh(D) diagnostic that identifies fetal DNA in maternal blood in all cases in which a diagnosis can be delivered-whether the fetus is male or female, Rh(D) negative or positive.

Until now, the only tests avai
'/>"/>

SOURCE Biocept
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
2. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
3. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
4. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
5. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
6. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
7. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
8. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
11. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biot...of vaccines, announced today that it executed,a jo...alian) Vaccine,Technology Co., Ltd. (Sinovac Dalia...mercialize human-use vaccines. Sinovac will contri...d commercializing world-class vaccines; the,other ...
(Date:11/24/2009)...lable in German . , Whether it,s CD packagi...(Radio Frequency Identification) are increasingly ... possible to label objects or goods and identify t...ate scanner can read and process the data containe...ds under production conditions of up to 100 degree...
(Date:11/24/2009)... The New York investment bank KTA Capital,s clie... an AU$6.7 mil convertible note private placement ...acement was arranged by KTA Capital as Neuren,s ex... New York (PRWEB) November 23, 2009 -...ital, LLC ("KTA Capital") has announced ...
(Date:11/24/2009)..., REYKJAVIK, Iceland, November 24 /PRNewswire-...) today announced that it has received notice from...ny,s common stock will be,suspended as of November...,Securities and Exchange Commission, which will re... unless the company files an appeal to the Nasdaq,...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...f., Sept. 10 Forterus,Inc. (OTC Bulletin Board: F...ent Center Inc., its behavioral healthcare subsidi...ry, a DNA-customized program for,individuals with ... "As one of the leading addiction treatment center...triving to improve its success rate with,addiction...
.... 10 SoluBest Ltd., a privately,held, clinical st...has,appointed Michael Sheckler, MBA, as CEO. Mr. S...erience to SoluBest., (Logo: http://www.newscom....kler began his career with the Ross Division of Ab...eutical products. During his,time there, he served...
...gy to Identify a New Generation of Drug Candidates... LONDON and CAMBRIDGE, England and PHILADELPHIA an...and GlaxoSmithKline (LSE & NYSE:,GSK) announce the...over,develop and market novel kinase-targeted ther...iance gives GSK access to Cellzome,s significant e...
Other Biology Technology:A Better Tomorrow Treatment Center Inc., Forterus Inc.'s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior 2SoluBest Appoints Michael Sheckler, MBA, as CEO 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 3GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 4
(Date:11/25/2009)...linchpin of the environment, where atmosphere, bio...tudents see soil as "just dirt" a place to grow p...e challenged with the task of helping students and...oil in the environment. , A collaborative proje...niversity of Nebraska-Lincoln, Oregon State Univer...
(Date:11/25/2009)...tal to your health as what you eat, found research...Their experiments in mice revealed that the daily ...erthe body,s metabolic clearinghouseis mostly cont...ian clock as conventional wisdom had it. , "If ...mber of genes completely independent of the circad...
(Date:11/24/2009)...standing how sounds associated with Navy sonar mig...ey hear it at all. , The same type of large indu...ct flaws in the space shuttle,s behemoth solid fue...e the giant head of a whale. The scans are providi...s hearing anatomy using a breakthrough method deve...
Breaking Biology News(10 mins):It's not just dirt! 2Feeding the clock 2Feeding the clock 3Rocket science leads to new whale discovery 2Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 1Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 2Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 1Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 2Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 3Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 4Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 5Obese Get Higher Doses of Radiation for X Rays 50432 1Obese Get Higher Doses of Radiation for X Rays 50432 2Obese Get Higher Doses of Radiation for X Rays 50432 3
...like a modern-day version of the David and Goliath...slay a big killer with pebbles. In this case, the ...ase: cancer. And the pebbles are not the kind you ...ads known as Photonic Explorers for Biomedical use..., First developed as sensors to explore and monito...
...al School geneticists have found links in the cell... avenues for studying and targeting a process vita...immune diseases. , The work, reported in the Febr...mitochondria, the cellular power plant, in prompti...y cell death models along the evolutionary spectru...
...ffymetrix, Inc. (Nasdaq: AFFX) reported today in S...high-resolution scan of structure and function for...n collaboration with the National Cancer Institute...microarrays to study every fifth base, on average,...s of regions of the genome are transcribed into ov...
Other Biology News:Taking Aim With Nanoparticle PEBBLEs 2Taking Aim With Nanoparticle PEBBLEs 3Critical role in programmed cell death identified 2Critical role in programmed cell death identified 3New Study from Affymetrix Laboratories Points to Changing View of How Genome Works 2New Study from Affymetrix Laboratories Points to Changing View of How Genome Works 3
Matrigel Matrix 100 mm Culture Dishes for Hepatocytes from BD Biosciences - Discovery Labware
Hae II Haemophilus aegyptius from Sigma-Aldrich
...5-OxoETE-d7 is used as an internal standard for th...ution mass spectrometry. 5-OxoETE is a polyunsatur...n human neutrophils. It stimulates cytosolic calci...xoETE selectively stimulates the migration and deg...
...The pAcAB4 vector is a 10.0 kb Autographa californ...tains two,copies of the AcNPV polyhedrin promoter ...st p10,promoter is a Sma I cloning site, followed ... Upstream of this,an inverted polyhedrin promoter...
Biology Products: